Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Uncomplicated urinary tract infection is a common bacterial condition primarily affecting otherwise healthy individuals, particularly women. UTIs occur up to four times more frequently in females than in males. In the United States, approximately 40% of women experience a UTI during their lifetime, while 10% report at least one episode annually. Recurrence is significant, with nearly 50% developing a second infection within one year, most commonly among women aged 16-35 years. The uncomplicated urinary tract infection pipeline analysis by Expert Market Research highlights ongoing innovation to address this high and recurrent disease burden.
-
Major companies involved in the uncomplicated urinary tract infection pipeline analysis include Johnson & Johnson, Fimbrion Therapeutics, and others.
-
Leading drugs currently in the pipeline include U101 and others.
-
Growth in the uncomplicated urinary tract infection (uUTI) pipeline is driven by escalating antimicrobial resistance to first-line oral antibiotics, renewed regulatory incentives for novel anti-infectives, and rising clinical emphasis on microbiome-sparing and single-dose therapies. Increasing female-focused drug development and rapid diagnostic integration are further accelerating targeted pipeline innovation.
Report Coverage
The Uncomplicated Urinary Tract Infection Pipeline Analysis Report by Expert Market Research gives comprehensive insights into uncomplicated urinary tract infection therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for uncomplicated urinary tract infection. The uncomplicated urinary tract infection report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The uncomplicated urinary tract infection pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with uncomplicated urinary tract infection treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uncomplicated urinary tract infection.
Read more about this report - Request a Free Sample
Uncomplicated Urinary Tract Infection Pipeline Outlook
The uncomplicated urinary tract infection (uUTI) pipeline outlook is strengthening with targeted therapies addressing rising antibiotic resistance and treatment gaps beyond traditional antibiotics like nitrofurantoin and trimethoprim-sulfamethoxazole.
Uncomplicated urinary tract infection treatment continues to evolve as standard care, which typically involves short-course oral antibiotics, faces mounting resistance challenges that drive the need for novel agents. In March 2025, the U.S. FDA approved Blujepa (gepotidacin), the first new class of oral antibiotic for uUTIs in nearly 30 years, offering a novel mechanism that inhibits bacterial DNA replication and expands options for females aged 12 and older. This milestone highlights robust late-stage development and demand for innovative uUTI treatments.
Uncomplicated Urinary Tract Infection Epidemiology
Uncomplicated urinary tract infection (uUTI) represents a substantial global epidemiological burden, particularly among otherwise healthy populations. Urinary tract infections remain one of the most common infections worldwide, with age-standardized incidence reaching approximately 5,531.88 per 100,000 persons in 2021, reflecting a rising trend. uUTIs disproportionately affect females, with women experiencing nearly four times higher incidence than men across most age groups, largely due to anatomical and hormonal factors. The highest incidence is observed in young and middle-aged adult women, while rates are comparatively lower in males and children. Recurrent episodes further amplify the clinical and economic burden of uUTIs globally.
Uncomplicated Urinary Tract Infection – Pipeline Therapeutic Assessment
This section of the report covers the analysis of uncomplicated urinary tract infection drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The uncomplicated urinary tract infection pipeline analysis report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibodies
- Small Molecules
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Uncomplicated Urinary Tract Infection Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total uncomplicated urinary tract infection clinical trials. The trial distribution shows that phase 2, phase 3, and phase 4 each account for 33%. Overall, this distribution highlights a balanced pipeline with strong mid- to late-stage clinical development activity in uncomplicated urinary tract infection therapies.
Uncomplicated Urinary Tract Infection Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the uncomplicated urinary tract infection pipeline analysis include small molecules, peptides, and monoclonal antibodies. The uncomplicated urinary tract infection report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for uncomplicated urinary tract infection. In April 2024, the U.S. Food and Drug Administration (FDA) approved Pivya (pivmecillinam) tablets for the treatment of adult women with uncomplicated urinary tract infections (uUTIs) caused by susceptible Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. This approval provides an additional oral antibiotic option beyond existing therapies, expanding the treatment landscape for one of the most common bacterial infections in women.
Uncomplicated Urinary Tract Infection Clinical Trials – Key Players
The EMR report for the uncomplicated urinary tract infection pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed, uncomplicated urinary tract infection therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in uncomplicated urinary tract infection clinical trials:
- Locus Biosciences
- TCM Biotech International Corp.
- Iterum Therapeutics
- Inmunotek
- Johnson & Johnson
- Fimbrion Therapeutics
- Wockhardt
- Helperby Therapeutics
- Seed Health, Inc.
- Aelin Therapeutics
Uncomplicated Urinary Tract Infection – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for uncomplicated urinary tract infection. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of uncomplicated urinary tract infection drug candidates.
Drug: LBP-EC01
LBP-EC01 is a bacteriophage-based therapy designed to selectively target Escherichia coli, the leading cause of uncomplicated urinary tract infections. It works by using naturally occurring bacteriophages to infect and lyse pathogenic bacteria without disrupting beneficial microbiota, addressing antibiotic resistance challenges. LBP-EC01 is being developed by Locus Biosciences, a biotechnology company focused on precision phage therapies for bacterial infections, leveraging proprietary engineering platforms to advance targeted antimicrobial solutions.
HMP in potency C200 or C1000
HMP in potency C200 or C1000 is a homeopathic medicinal product investigated for symptom management in uncomplicated urinary tract infections. It is designed to stimulate the body’s self-regulatory mechanisms to reduce urinary discomfort and inflammation rather than directly eradicating pathogens. Studies involving this product are typically conducted by academic or alternative medicine research groups, which focus on evaluating safety, tolerability, and potential supportive benefits alongside conventional antibiotic therapy in uUTI management.
Drug: U101
U101 is a small-molecule antibiotic candidate under investigation for treating uncomplicated urinary tract infections caused by common uropathogens. It is designed to inhibit bacterial growth through targeted disruption of essential microbial pathways, aiming to retain efficacy against resistant strains while minimizing systemic exposure. U101 is being studied by UroPharma-focused biotechnology developers, which specialize in urogenital infectious diseases and are advancing novel oral therapies to improve treatment convenience and resistance profiles.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Uncomplicated Urinary Tract Infection Pipeline Insight Report
- Which companies/institutions are leading the uncomplicated urinary tract infection drug development?
- Which company is leading the uncomplicated urinary tract infection pipeline development activities?
- What is the current uncomplicated urinary tract infection commercial assessment?
- What are the opportunities and challenges present in the uncomplicated urinary tract infection pipeline landscape?
- What is the efficacy and safety profile of uncomplicated urinary tract infection pipeline drugs?
- Which company is conducting major trials for uncomplicated urinary tract infection drugs?
- Which companies/institutions are involved in uncomplicated urinary tract infection collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in uncomplicated urinary tract infection?
Reasons To Buy This Report
The Uncomplicated Urinary Tract Infection Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for uncomplicated urinary tract infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into uncomplicated urinary tract infection collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Complicated Urinary Tract Infections Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share